Corbett Accel taps Cooper-Broski as new EVP,CMO

Share this article:

Omnicomm unit Corbett Accel Healthcare Group has hired 30-year advertising veteran Elisa Cooper-Broski, to serve as its new EVP and chief marketing officer (CMO).

In her new role, Cooper-Broski will direct Corbett Accel's business development strategy and lead brand-building efforts for the company's five business units in conjunction with the business unit leaders.

Cooper-Broski will be based in Corbett Accel's New York office and will report directly to CEO Scott Cotherman.

“The CMO role is relatively unknown in pharmaceutical advertising,” said Cotherman. "We are one of the first to identify the value a chief marketing officer brings to an organization. Elisa Cooper-Broski's extensive knowledge of the pharmaceutical industry, along with her multi-faceted experience, will be invaluable as we advance our integrated business development strategy."

Cooper-Broski previous experience includes work with GSW New York's presence, Saatchi & Saatchi Healthcare (formerly Klemtner Advertising) CommonHealth USA and NCI Advertising (formerly Rolf Werner Rosenthal).

Prior to joining Corbett Accel, Cooper-Broski was president and chief branding officer for Bruce Leeb & Company, a privately held healthcare advertising agency.

“In this environment, my role as CMO will strengthen the overall impact of Corbett Accel and its business units in the pharmaceutical industry as a communications company that delivers visionary results with substantial and beneficial outcomes” said Cooper-Broski in a statement.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...